EA200300572A1 - Комбинированная терапия эстроген-зависимых заболеваний - Google Patents

Комбинированная терапия эстроген-зависимых заболеваний

Info

Publication number
EA200300572A1
EA200300572A1 EA200300572A EA200300572A EA200300572A1 EA 200300572 A1 EA200300572 A1 EA 200300572A1 EA 200300572 A EA200300572 A EA 200300572A EA 200300572 A EA200300572 A EA 200300572A EA 200300572 A1 EA200300572 A1 EA 200300572A1
Authority
EA
Eurasian Patent Office
Prior art keywords
estrogen
combined therapy
dependent diseases
dependent
testicles
Prior art date
Application number
EA200300572A
Other languages
English (en)
Inventor
Динеш Пурандаре
Original Assignee
Фармация Энд Апджон Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Энд Апджон Компани filed Critical Фармация Энд Апджон Компани
Publication of EA200300572A1 publication Critical patent/EA200300572A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение касается комбинированной терапии эстроген-зависимых злокачественных опухолей у восприимчивых млекопитающих, включая человека, состоящей из этапов ингибирования гормональной продукции их яичек или яичников, соответственно, и введения указанному млекопитающему по меньшей мере одного ингибитора ароматазы.
EA200300572A 2000-11-16 2001-11-06 Комбинированная терапия эстроген-зависимых заболеваний EA200300572A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71460500A 2000-11-16 2000-11-16
PCT/US2001/043847 WO2002039995A2 (en) 2000-11-16 2001-11-06 Combination therapy for estrogen-dependent disorders

Publications (1)

Publication Number Publication Date
EA200300572A1 true EA200300572A1 (ru) 2004-06-24

Family

ID=24870727

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300572A EA200300572A1 (ru) 2000-11-16 2001-11-06 Комбинированная терапия эстроген-зависимых заболеваний

Country Status (16)

Country Link
EP (1) EP1341549A2 (ru)
JP (1) JP2004536022A (ru)
KR (1) KR20030051828A (ru)
CN (1) CN1498112A (ru)
AU (1) AU2002230464A1 (ru)
BR (1) BR0115423A (ru)
CA (1) CA2428249A1 (ru)
CZ (1) CZ20031349A3 (ru)
EA (1) EA200300572A1 (ru)
IL (1) IL155817A0 (ru)
MX (1) MXPA03004195A (ru)
NO (1) NO20032206L (ru)
NZ (1) NZ525720A (ru)
PL (1) PL365904A1 (ru)
WO (1) WO2002039995A2 (ru)
ZA (1) ZA200303669B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
GB0506759D0 (en) * 2005-04-02 2005-05-11 Medical Res Council Combination treatment methods
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
JP2010524996A (ja) * 2007-04-23 2010-07-22 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Ｂｒｃａ媒介性疾患における使用のための、プロゲステロン受容体拮抗薬と、ルテインホルモン放出ホルモン作動薬および拮抗薬との組み合わせ
CN101775054B (zh) * 2010-02-05 2012-12-26 常州佳尔科药业集团有限公司 4-羟基-4-烯-3-酮甾族化合物的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9911582D0 (en) * 1999-05-18 1999-07-21 Pharmacia & Upjohn Spa Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia

Also Published As

Publication number Publication date
WO2002039995A9 (en) 2003-02-06
NO20032206L (no) 2003-07-15
NZ525720A (en) 2006-12-22
MXPA03004195A (es) 2003-09-22
WO2002039995A2 (en) 2002-05-23
AU2002230464A1 (en) 2002-05-27
IL155817A0 (en) 2003-12-23
WO2002039995A3 (en) 2003-05-01
ZA200303669B (en) 2004-05-13
NO20032206D0 (no) 2003-05-15
PL365904A1 (en) 2005-01-10
EP1341549A2 (en) 2003-09-10
CN1498112A (zh) 2004-05-19
BR0115423A (pt) 2005-12-13
CZ20031349A3 (cs) 2004-05-12
CA2428249A1 (en) 2002-05-23
JP2004536022A (ja) 2004-12-02
KR20030051828A (ko) 2003-06-25

Similar Documents

Publication Publication Date Title
DK1187918T4 (da) TEK-antagonister
MY137766A (en) Exemestane as chemopreventing agent
MXPA03002778A (es) Polipeptidos antiangiogenicos y metodos para inhibir angiogenesis.
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BG106738A (en) A method for chemoprevention of prostate cancer
DE60231439D1 (de) Mitotische kinesinhemmer
DE60234278D1 (de) Mitotische kinesin-hemmer
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
ATE303156T1 (de) Verwendung von gnrh-analogue zur behandlung der harninkontinenz
SE9800836D0 (sv) New Compounds
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
TR200101895T2 (tr) Cinsel rahatsızlıkların tedavisi.
NO20075849L (no) Fremgangsmater og preparater til behandling eller forebygging av kreft
TR200101120T2 (tr) Serin proteaz inhibitörü
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
EA200500244A1 (ru) Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии
TR200003443T2 (tr) Geçmeyen depresyonun tedavisi için kombinasyon terapisi
EA200201276A1 (ru) Производные арилметиламина для использования в качестве ингибиторов триптазы
ES2163795T3 (es) Composicion farmaceutica contra los tumores e infecciones por papilomavirus.
NO20051040L (no) Anvendelse av alkylfosfokoliner i kombinasjon med antitumormedikamenter
ATE412412T1 (de) Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1 -pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata-oder gebahrmutterkrebs
EA200300572A1 (ru) Комбинированная терапия эстроген-зависимых заболеваний
ATE489103T1 (de) Gezielte thrombose durch gewebefaktor polypeptiden
PA8453601A1 (es) Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para tratamiento del cancer